These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 20012265)
1. Prostaglandins of the E series inhibit monoamine release via EP3 receptors: proof with the competitive EP3 receptor antagonist L-826,266. Günther J; Schulte K; Wenzel D; Malinowska B; Schlicker E Naunyn Schmiedebergs Arch Pharmacol; 2010 Jan; 381(1):21-31. PubMed ID: 20012265 [TBL] [Abstract][Full Text] [Related]
2. E-ring 8-isoprostanes inhibit ACh release from parasympathetic nerves innervating guinea-pig trachea through agonism of prostanoid receptors of the EP3-subtype. Clarke DL; Giembycz MA; Patel HJ; Belvisi MG Br J Pharmacol; 2004 Feb; 141(4):600-9. PubMed ID: 14744812 [TBL] [Abstract][Full Text] [Related]
3. Mutual interactions of the presynaptic histamine H3 and prostaglandin EP3 receptors on the noradrenergic terminals in the mouse brain. Schlicker E; Marr I Neuroscience; 1997 Jul; 79(1):247-54. PubMed ID: 9178880 [TBL] [Abstract][Full Text] [Related]
4. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta. Schultheiss T; Flau K; Kathmann M; Göthert M; Schlicker E Naunyn Schmiedebergs Arch Pharmacol; 2005 Aug; 372(2):139-46. PubMed ID: 16195872 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Nakazi M; Bauer U; Nickel T; Kathmann M; Schlicker E Naunyn Schmiedebergs Arch Pharmacol; 2000 Jan; 361(1):19-24. PubMed ID: 10651142 [TBL] [Abstract][Full Text] [Related]
6. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Kathmann M; Bauer U; Schlicker E; Göthert M Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):466-70. PubMed ID: 10431757 [TBL] [Abstract][Full Text] [Related]
7. Prostanoid receptors of the EP3 subtype mediate the inhibitory effect of prostaglandin E2 on noradrenaline release in the mouse brain cortex. Exner HJ; Schlicker E Naunyn Schmiedebergs Arch Pharmacol; 1995 Jan; 351(1):46-52. PubMed ID: 7715741 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of noradrenaline release in the rat vena cava via prostanoid receptors of the EP3-subtype. Molderings G; Malinowska B; Schlicker E Br J Pharmacol; 1992 Oct; 107(2):352-5. PubMed ID: 1330175 [TBL] [Abstract][Full Text] [Related]
9. EP₃ receptor-mediated contraction of human pulmonary arteries and inhibition of neurogenic tachycardia in pithed rats. Kozłowska H; Baranowska-Kuczko M; Schlicker E; Kozłowski M; Zakrzeska A; Grzęda E; Malinowska B Pharmacol Rep; 2012; 64(6):1526-36. PubMed ID: 23406763 [TBL] [Abstract][Full Text] [Related]
10. Modulation of noradrenaline release from the sympathetic nerves of the human saphenous vein and pulmonary artery by presynaptic EP3- and DP-receptors. Molderings GJ; Colling E; Likungu J; Jakschik J; Göthert M Br J Pharmacol; 1994 Mar; 111(3):733-8. PubMed ID: 8019753 [TBL] [Abstract][Full Text] [Related]
11. Modulation of dopamine release in the guinea-pig retina by G(i)- but not by G(s)- or G(q)-protein-coupled receptors. Weber B; Schlicker E Fundam Clin Pharmacol; 2001 Dec; 15(6):393-400. PubMed ID: 11860527 [TBL] [Abstract][Full Text] [Related]
12. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Schlicker E; Timm J; Zentner J; Göthert M Naunyn Schmiedebergs Arch Pharmacol; 1997 Nov; 356(5):583-9. PubMed ID: 9402037 [TBL] [Abstract][Full Text] [Related]
13. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Lawrence RA; Jones RL; Wilson NH Br J Pharmacol; 1992 Feb; 105(2):271-8. PubMed ID: 1559125 [TBL] [Abstract][Full Text] [Related]
14. Modulation of noradrenaline release from the sympathetic nerves of human right atrial appendages by presynaptic EP3- and DP-receptors. Molderings GJ; Likungu J; Göthert M Naunyn Schmiedebergs Arch Pharmacol; 1998 Oct; 358(4):440-4. PubMed ID: 9826066 [TBL] [Abstract][Full Text] [Related]
15. Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein. Lawrence RA; Jones RL Br J Pharmacol; 1992 Apr; 105(4):817-24. PubMed ID: 1324050 [TBL] [Abstract][Full Text] [Related]
16. Possible involvement of brain prostaglandin E2 and prostanoid EP3 receptors in prostaglandin E2 glycerol ester-induced activation of central sympathetic outflow in the rat. Shimizu T; Tanaka K; Nakamura K; Taniuchi K; Yawata T; Higashi Y; Ueba T; Dimitriadis F; Shimizu S; Yokotani K; Saito M Neuropharmacology; 2014 Jul; 82():19-27. PubMed ID: 24657150 [TBL] [Abstract][Full Text] [Related]
17. A search for presynaptic beta3-adrenoceptors in the rat. Zelaszczyk D; Zakrzeska A; Kwolek G; Malinowska B; Schlicker E Fundam Clin Pharmacol; 2005 Apr; 19(2):147-53. PubMed ID: 15810894 [TBL] [Abstract][Full Text] [Related]
18. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. Kathmann M; Weber B; Schlicker E Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):50-6. PubMed ID: 11191836 [TBL] [Abstract][Full Text] [Related]
19. Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Schlicker E; Timm J; Göthert M Naunyn Schmiedebergs Arch Pharmacol; 1996 Dec; 354(6):791-5. PubMed ID: 8971741 [TBL] [Abstract][Full Text] [Related]
20. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease. Heptinstall S; Espinosa DI; Manolopoulos P; Glenn JR; White AE; Johnson A; Dovlatova N; Fox SC; May JA; Hermann D; Magnusson O; Stefansson K; Hartman D; Gurney M Platelets; 2008 Dec; 19(8):605-13. PubMed ID: 19012178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]